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Abstract
Background: Mutations in MYBPC3 encoding myosin binding protein C belong to the most
frequent causes of hypertrophic cardiomyopathy (HCM) and may also lead to dilated
cardiomyopathy (DCM). MYBPC3 mutations initially were considered to cause a benign form of
HCM. The aim of this study was to examine the clinical outcome of patients and their relatives with
18 different MYBPC3 mutations.
Methods: 87 patients with HCM and 71 patients with DCM were screened for MYBPC3 mutations
by denaturing gradient gel electrophoresis and sequencing. Close relatives of mutation carriers
were genotyped for the respective mutation. Relatives with mutation were then evaluated by
echocardiography and magnetic resonance imaging. A detailed family history regarding adverse
clinical events was recorded.
Results: In 16 HCM (18.4%) and two DCM (2.8%) index patients a mutation was detected. Seven
mutations were novel. Mutation carriers exhibited no additional mutations in genes MYH7, TNNT2,
TNNI3, ACTC and TPM1. Including relatives of twelve families, a total number of 42 mutation
carriers was identified of which eleven (26.2%) had at least one adverse event. Considering the
twelve families and six single patients with mutations, 45 individuals with cardiomyopathy and nine
with borderline phenotype were identified. Among the 45 patients, 23 (51.1%) suffered from an
adverse event. In eleven patients of seven families an unexplained sudden death was reported at
the age between 13 and 67 years. Stroke or a transient ischemic attack occurred in six patients of
five families. At least one adverse event occurred in eleven of twelve families.
Conclusion: MYBPC3 mutations can be associated with cardiac events such as progressive heart
failure, stroke and sudden death even at younger age. Therefore, patients with MYBPC3 mutations
require thorough clinical risk assessment.
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Background
Hypertrophic cardiomyopathy (HCM) is a common dis-
ease with an estimated prevalence of 1:500 in north amer-
icans [1]. The disease may remain without clinical
symptoms for many years. HCM has been recognized as
the most common cause of sudden cardiac death in the
young, especially in competitive athletes, where it
accounts for 26% of cases [2]. Therefore, early diagnosis is
crucial for prevention of such catastrophic events. For risk
stratification, an expert based recommendation exists,
which is mainly based on clinical findings such as maxi-
mum wall thickness [3], abnormal blood pressure
response during exercise and non-sustained ventricular
tachycardia [4]. Additionally, a positive family history for
sudden cardiac death as a correlate of malignant gene
mutations was recognized as an independent risk factor.
Most cases of HCM are a result of mutations in genes
encoding the sarcomeric proteins β-myosin heavy chain
(MYH7), myosin binding protein C (MYBPC3), troponin
T (TNNT2), troponin I (TNNI3), cardiac α-actin (ACTC)
and α-tropomyosin (TPM1). Certain mutations in MYH7
and TNNT2 were ascribed a poor disease prognosis [5],
while MYBPC3 mutations were attributed a more benign
course and a low disease penetrance [6,7].
Dilated cardiomyopathy (DCM) is a major cause of heart
failure in the young and accounts for about half of all
heart transplantations. It is estimated that up to 35% of
DCM cases are familial, indicative of potential gene muta-
tions [8]. While HCM is mostly caused by mutations in
sarcomeric protein genes, the genetic causes of familial
DCM are more heterogeneous and hence, are less well
defined. Up to 10% of familial DCM cases may be the
result of mutations in sarcomeric protein genes like
MYH7,  MYBPC3  and  TNNT2  [9]. Besides these genes,
many others encoding cytoskeletal and nuclear envelope
proteins, channel proteins and those encoding factors
involved in calcium cycling were identified as candidates
for DCM (for review [10]).
Here we studied the clinical outcome of families with
HCM or DCM and mutations in MYBPC3, particularly
with respect to adverse events like progressive heart fail-
ure, sudden cardiac death and stroke.
Methods
Patients
Patients presenting at the catheterization laboratory, car-
diac MRI or outpatient department of our university hos-
pital with a new or previously established diagnosis of a
primary HCM or DCM were recruited for the study after
written consent. Patients from external cardiologists were
included, if a written consent and a blood sample was
available. The diagnosis of primary HCM or DCM was
established according to international standards. In short,
HCM was defined by left ventricular wall thickening of 13
mm or more in the absence of secondary causes [11].
DCM was defined as depressed left ventricular ejection
fraction less than 45% and a left ventricular end-diastolic
diameter (LVEDD) of more than 117% of the expected
value [12]. Echocardiography was performed in all
patients according national and international standards.
LVEDD was obtained from M-Mode recordings, maxi-
mum wall thickness and left ventricular ejection fraction
(LVEF) form two dimensional echocardiography. LVEF
was classified as follows: Normal ≥ 55%, mildly impaired
45–54%, moderately 30–44% and severely < 30% [13].
The study protocol was approved by the ethics committee
of the medical faculty at the University of Heidelberg.
Cardiac MRI
After exclusion of contraindications, cardiac MRI was per-
formed in supine position at end-expiration employing
an 1.5 Tesla, whole body superconducting MRI scanner
system (ACHIEVA, Philips Medical Systems, Best, the
Netherlands) using a five-element cardiac phased array
surface coil with vector ECG-gating. Assessment of resting
LV function was determined by cine images using a
steady-state free precession sequence (matrix = 160/256,
sense-factor = 2, flip-angle = 60°, slice thickness/gap = 8/
2 mm) in continuous short axes covering the whole left
and right ventricle from base to apex as well as 2-, 3- and
4-chamber views in anatomically correct heart axes. MRI
data was transferred to a clinical workstation (Viewforum,
Philips Medical Systems, Best, the Netherlands). End-
diastolic (EDV, ml) and -systolic (ESV, ml) volumes and
resulting ejection fraction (EF in %) were measured man-
ually using short axes volumetry by determination of end-
diastolic and -systolic cine images and subsequent deline-
ation of endocardial borders excluding papillary muscles.
For evaluation of myocardial mass, borders were also
drawn at the interface between myo- and epicardium on
end-diastolic images including papillary muscles. For ana-
tomical description of late enhancement localisation, the
AHA 17 segment model was employed consisting of six
basal, six mid-ventricular, four apical segments as well as
the apex. The signal intensities of late enhancement were
described qualitatively (massive, normal, discrete) by
consensus decision of the two observers.
Mutation screening
87 patients with HCM and 71 patients with DCM were
screened by denaturing gradient gel electrophoresis
(DGGE) and subsequent sequencing for mutations in
coding exons and flanking intron sequences of the
MYBPC3 gene as described previously [14]. In an experi-
ment of our previous study [14] testing the sensitivity of
DGGE, 16 of 16 sequence verified variants among 187 dif-
ferent patient samples were accurately identified, indicat-
ing the excellent sensitivity of the method. All patientsBMC Medical Genetics 2008, 9:95 http://www.biomedcentral.com/1471-2350/9/95
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with mutations in MYBPC3 were additionally screened for
mutations by single-strand conformational polymor-
phism analysis as already described [15] in cardiac tro-
ponin I (TNNI3; exon 8 screened by direct sequencing) or
by DGGE in β-myosin heavy chain (MYH7; with the
exception of exon 27), cardiac troponin T (TNNT2), car-
diac α-actin (ACTC) and α-tropomyosin (TPM1; with the
exception of exon 1). The primer sequences used in this
study are available on request. To examine whether newly
identified  MYBPC3  mutations are present in "healthy"
individuals and, therefore, to be considered as polymor-
phisms rather than as disease-causing mutations, 430
control persons with normal systolic and diastolic func-
tion were screened for these new mutations by DGGE.
These controls were patients recruited from our cardiac
catheterization laboratory, had no significant stenoses
revealed by coronary angiography and no evidence for
any myocardial disease
Family screening
All first and second degree relatives of patients with a
MYBPC3 mutation were asked to participate in our family
screening program. Screening always included ecg and
echocardiography. If an examination had been already
performed by an external cardiologist, patients were asked
for permission to request the examination record from
their physicians. Furthermore, all relatives were invited to
participate in the genetic screening and, if screened posi-
tive for a mutation, for additional cardiac MRI. This was
performed in 16 of 42 mutation carriers. If possible, a
pedigree of up to four generations together with a detailed
family history was recorded. Deceased family members
were considered affected if a sudden unexplained death
occurred at or below 35 years of age [12]. Affection was
presumed if a family member suffered from sudden death
at 50 years of age or younger. Genetic counselling was
offered to all participants and their families.
Results
MYBPC3 mutations in HCM and DCM patients
18 different mutations (four splice, three frameshift,
seven missense, three nonsense mutations and one in-
frame codon deletion), distributed throughout almost the
entire gene, from intron 2 to exon 34, were found in 18
patients (Tables 1 and 2, Fig. 1). Close relatives of muta-
tion carriers were subsequently genotyped for the respec-
tive mutation. Seven mutations were considered novel,
since they were neither found in the large MYBPC3 muta-
tion list of the "Cardiogenomics" database http://genet
ics.med.harvard.edu/~seidman/cg3/muts/
MYBPC3_mutations_TOC.html, nor in the SNP database
dbSNP http://www.ncbi.nlm.nih.gov/projects/SNP/, nor
in one of recent articles found in PubMed http://
www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed describ-
ing novel mutations in the MYBPC3 gene. The causal role
of the new mutations in the disease was underscored by
their absence in 430 control individuals with normal
systolic and diastolic function and, in one case (family
16), familial co-segregation with the disease. Moreover,
four of the seven new mutations lead to a significant
change of the amino acid sequence, namely two splice site
mutations, one frameshift mutation and one nonsense
mutation. A fifth mutation, p.R272C, altered one of three
known phoshorylation motifs of the MYBP-C protein
[16]. Preliminary analyses revealed a threefold decrease in
the phosphorylation of a mutant p-R272C MYBP-C pep-
tide fragment compared to the wild type fragment
(unpublished data), yet the functional consequence of the
mutation in vivo is still unknown. The two remaining mis-
sense mutations are considered functionally relevant since
both affect highly conserved amino acid positions (Fig.
2).
Two new mutations were found in DCM patients of fam-
ilies 5 and 16, while all other mutations were detected in
patients with HCM. One patient was a double-heterozy-
gote for two different missense mutations located in exons
7 and 28. Members of the two unrelated families 17 and
18 had the same Gln1233ter nonsense mutation, which
terminates the MYBP-C protein prematurely, leading to
loss of 42 of the 1274 amino acids. This mutation had
been described previously as a polymorphism [17], based
on its presence in 2% of 200 phenotypically uncharacter-
ized control individuals. We and others, however, consid-
ered the mutation disease-causing, since it was neither
detected in 350 controls in previous studies [18,19], nor
in our 430 controls. Moreover, the mutation clearly segre-
gated with the disease in all five mutation carriers of fam-
ily 17, either associated with a HCM phenotype or with
borderline myocardial hypertrophy (IV-2).
To exclude mutations in other genes of high relevance in
cardiomyopathies, the 18 initial mutation carriers were
screened additionally for mutations in MYH7, TNNT2,
TNNI3, ACTC and TPM1 encoding β-myosin heavy chain,
cardiac troponin T, cardiac troponin I, cardiac α-actin and
α-tropomyosin, respectively. No further mutations were
found in these genes.
Phenotypic heterogeneity of mutation carriers
We observed a broad spectrum of phenotypes among the
mutation carriers: from asymptomatic and phenotypically
normal at the age of 85, like I-2 of family 5 (Table 2), to
heavily affected at a relatively young age, like III-9 of fam-
ily 16 at the age of 44 or IV-3 of family 12 at the age of 13
(Tables 2 and 3). Even close relatives carrying the same
mutation displayed a striking phenotypic heterogeneity,
as documented by members of families 5, 12, 16 and 17.BMC Medical Genetics 2008, 9:95 http://www.biomedcentral.com/1471-2350/9/95
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The index patient of family 5, II-2, initially presented with
decompensated heart failure during new onset of tachyar-
rhythmic atrial fibrillation and arterial hypertension. In
addition, cardiac catheterization ruled out significant cor-
onary artery disease, but revealed an enlarged left ventricle
with severely depressed systolic function. The patient
improved, however, under guideline-conform treatment,
as documented four years later by cardiac MRI displaying
normalized left ventricular function and only minor path-
ological findings regarding wall thickness and myocardial
late contrast enhancement. The son, III-2, had a mild
enlargement of the left ventricle with an end-diastolic vol-
ume index of 98.1 ml/m2 during MRI (reference value 47–
92 ml/m2). However, he and his father showed a marked
trabeculation on cardiac MRI. This finding did not fulfil
the criteria for myocardial noncompaction, but might be
an explanation for the overestimated wall thickness by
echocardiography. Two further mutation carriers of fam-
ily 5, I-2 and II-6, were asymptomatic and, as revealed by
cardiac MRI, showed no phenotypical abnormalities.
Table 1: MYBPC3 mutations detected in this study
No. of family or 
single patient
Exon/IVS* Nucleotide posi-
tion† and change
Amino acid change Affected‡ Genotyped total/
pos.
Reference, 
comment
1 IVS1 c.26-2A>G unknown 3 (1) 2/2 Novel (similar [17])
2 2 c.141delT p.S47fs 3 2/2 Novel
3 6 c.711C>A p.Y237X 1 1/1 Novel
4 6 c.772G>A p.E258K 1 1/1 [6,22,25-27]
5 7 c.814C>T p.R272C 1 (1) 6/4 Novel§
6 IVS11 c.927-2A>G unknown 2 (1) 4/2 [6,25]
7 12 c.1006A>G p.I336V 1 1/1 Novel
8 15 c.1235_1236delTT p.F412fs 2 2/2 [17,25]
9 17 c.1484G>A p.R495Q 1 1/1 [6,17,28]
10 17 c.1505G>A p.R502Q 1 1/1 [6,21,29]
11 18 c.1699_1670delGA p.E567fs 3 3/2 [17]
12 IVS23 c.2308+1G>A unknown 5 (3) 8/5 [19,25]
13 25 c.2437_2439delAAG p.K814del 2 (1) 1/1 [17,27,29,30]
14 26 c.2670G>A p.W890X 3 5/2 [17]
15 27 c.2870C>G p.T957S 1 1/1 Novel
4 27 c.2873C>T p.T958I 1 1/1 [31]
16 IVS31 c.3490+1G>T unknown 7 7/6 Novel§ (similar [32])
17 33 c.3697C>T p.Q1233X 4 (1) 6/5 [18,19]; 
polymorphism [17]
18 33 c.3697C>T p.Q1233X 3 (1) 3/2
*IVS: intervening sequence; †Numbering refers to the coding sequence of GenBank acc. no. U91629http://www.ncbi.nlm.nih.gov/entrez/
viewer.fcgi?val=U91629.1 starting with the A of start codon ATG as position 1; ‡additional relatives with suspected disease in brackets; §DCM 
phenotype of the index patientBMC Medical Genetics 2008, 9:95 http://www.biomedcentral.com/1471-2350/9/95
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Table 2: Clinical characteristics of mutation carriers
No.* Indiv. Sex Age Age at first 
presentation 
(Diagnosis)
ECG*** Echo MRI
MWT† (mm) LVEF‡ MWT† (mm) LVEF (%) Late enhancement
1 II-3§ m 56 49 (HCM) SR, CV 28 n 27 60 mid-, inferoseptal and 
inferior basal
II-9 m 55 53 (HCM) AF, LBBB 30 n-↓ 33 51 massive septal, 
anterior, inferior
2 II-1§ m 55 55 (HCM) pxAF 24 n
III-1 f 30 30|| (HCM) SR 15 n
3S P # m 71 67 (HCM) AF 20 n-↓
4S P # m 48 46 (HCM) SR, CV, iLBBB 25 ↓
5 I-2 f 85 n.a. (-) AF 11 n
II-2§ m 65 62 (DCM) SR, CV 15†† n1 2 . 57 2 ‡‡ discrete septal 
(mid and basal)
II-6 f 55 55|| (-) SR 10 n < 11 65 none
III-2 m 38 38 (susp.) SR 14†† n<  1 16 2 §S none
6 II-2 f 68 n.a. (HCM) SR n.a.
III-1§ m 39 18 (HCM) SR n.a.
7S P # f 52 45 (HCM) SR, CV n.a. n
8I - 2f 7 1 6 9 || (HCM) SR 20 n
II-1§ m 49 35 (HCM) SR, AVB1, pxAF 25 ↓ 26 71 n.a.
9S P # f 66 44 (HCM) SR, pxAF 24 n
10 SP# m 54 54 (HCM) SR 22 n
11 II-3 m 66 66|| (HCM) AF 20 n
II-6§ f 62 54 (HCM) SR 22 n-↓
12 II-6 m 67 67|| (susp.) SR, LAHB 12 n
III-1 m 46 42|| (HCM) SR 14 n 21 54 massive intramural 
basal- and mid-septal
III-3§ m 42 37 (HCM) SR 30 n
IV-4 f 20 20|| ( H C M ) S R 1 4n1 4 7 7 n o n e
IV-5 f 14 14|| ( s u s p . ) S R 1 3n1 1 6 6 n o n e
13 II-1 m 54 54 (HCM) SR 13 n
II-6§ m 42 21 (HCM) SR 27 ↓
14 II-2§ f 61 57 (HCM) SR 14|| n
II-5 m 55 55|| (HCM) SR 18 n 20 74 mid and basal septal
15 SP# m 49 49 (HCM) SR 19 n 24 62 anteroseptal basal
16 II-3§ m6 6 ## 57 (DCM) AF n.a.## ↓↓↓##
II-5 m 65 34 (DCM) AF, LBBB 12 ↓↓↓
III-3 m 42 18 (HCM) SR 15 n 22 67 intense septal
III-6 f 40 40|| (HCM) SR 15 n
III-7 f 39 39|| (HCM) SR 15 n 14.5 72 septal, inferoseptal 
basal
III-9 f 44 44|| (HCM) SR, iLBBB 16 n 22 71 midseptal and 
inferoseptal basal
17 II-3§ m 72 n.a. (HCM) AF, RBBB 16 n
III-6 m 48 n.a. (HCM) SR 24 n
III-8 f 43 43|| (HCM) SR 10 n 13.5 65 discrete basal-septal
III-9 m 42 42|| (HCM) SR 18 n
IV-2 m 17 17|| (susp.) SR 12 n
18 II-4§ f 37 27 (HCM) SR 23 n 24 66 massive intramural 
basal- and mid-septal
III-5 m 15 15|| (susp.) SR 12 n
*Number of family or single patient (SP); †MWT: maximum wall thickness; ‡Left ventricular ejection fraction (n: normal; ↓: mildly reduced, ↓↓↓: 
severely reduced); §Index patient; ||First presentation due to screening program; #single patient; **n.a.: not available; ††marked trabeculation; ‡‡ End 
diastolic volume 205 ml, EDV index 94.9 ml/m2 (reference value 47–92 ml/m2); §§ End diastolic volume 212 ml, EDV index 98.1 ml/m2; || ||4 years after 
transcoronary ablation of septal hypertrophy; ##heart transplantation with 58 years; ***ECG: electrocardiogram; SR: sinus rhythm; CV: status after 
electrical cardioversion due to atrial fibrillation; AF: atrial fibrillation; pxAF: paroxysmal AF; LBBB: left bundle branch block; iLBBB: incomplete 
LBBB; AVB1: first degree atrio-ventricular block; LAHB: left-anterior hemiblock; RBBB: right bundle branch blockBMC Medical Genetics 2008, 9:95 http://www.biomedcentral.com/1471-2350/9/95
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Pedigrees of affected families: Open and black symbols represent unaffected and affected individuals, respectively Figure 1
Pedigrees of affected families: Open and black symbols represent unaffected and affected individuals, respec-
tively. Dashed symbols indicate individuals with presumed or borderline disease phenotype. Grey symbols denote individuals 
with unknown clinical status. (+) and (-) symbols indicate presence and absence of the mutation, respectively. Index patients 
are marked by an arrow. Slanted bars denote deceased individuals.
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In family 16, the index patient, II-3, and his brother, II-5,
had a DCM phenotype. In contrast, the other mutation
carriers, all belonging to the third generation of family 16,
displayed a HCM phenotype upon cardiac MRI examina-
tion, yet were otherwise asymptomatic. Only in individ-
ual III-3, a HCM was diagnosed before during a routine
physical examination.
The index patient of family 12 (III-3) had a severe left ven-
tricular hypertrophy with outflow obstruction, which
required septal ablation. His son (IV-3), who suffered
from sudden cardiac death at the age of 13 years, also had
a severe hypertrophy. In contrast, the index patient's
mother (II-6), also mutation carrier, had only a borderline
hypertrophy. In this patient, a comorbidity with a coro-
nary heart disease and previous inferior infarction was
prevalent, and the ventricular arrhythmias found at holter
monitoring might be a result from a myocardial scar after
inferior infarction.
In family 17, the index patient, II-3, presented at the age
of 72 years with a leading finding of a restrictive patho-
physiology and only a mild wall thickening, which prob-
ably was a result of an end-stage HCM. Unfortunately,
high-quality cardiac MRI recording was impossible due to
atrial fibrillation. All three children of this patient were
mutation carriers; only one was previously diagnosed
with HCM, while the other son and the daughter were
diagnosed with HCM in the course of our family screen-
ing.
Adverse clinical events
Malignant clinical events such as unexplained sudden
death, stroke or transient ischemic attack were ascertained
in many members of our study families (Table 3). Based
on twelve families and six single patients, a total number
of 42 mutation carriers was identified, of which eleven
had at least one adverse event. A total number of any
adverse event occured in 23 of 45 (51.1%) cardiomyopa-
thy cases. Eleven individuals of seven families suffered
from sudden death between 13 and 67 years of age. In
three families, a sudden death occurred at or before the
age of 35 years. Any adverse event occurred in eleven of
twelve families and in two of six single mutation carriers.
The youngest, IV-3 of family 12, already diagnosed with
an extreme septal hypertrophy and a dynamic outflow
obstruction, died at the age of 13. Moreover, a first degree
relative, II-3, of a mutation carrier in the same family
experienced sudden death at the age of 33. In family 16, a
sudden death occurred only shortly after the diagnosis of
HCM had been ascertained in the course of family screen-
ing. The female patient, III-9, had no heart failure symp-
toms but a maximum wall thickness of 22 mm, moderate
late enhancement during contrast MRI and mild elevated
NT-proBNP. Clinical findings in the patient did not qual-
ify for an implantable cardioverter defibrillator (ICD)
based on available risk scores [4]. A formerly asympto-
matic individual, II-1, of the same family suffered from
sudden cardiac death at the age of 32 in relation to exer-
cise. This patient had not been genotyped, yet can be con-
sidered mutation carrier based on the fact that his two
brothers, II-3 and II-5, and two symptomatic children, III-
3 and III-6, are mutation carriers.
Five patients of four families received an ICD for primary
prevention because of non-sustained ventricular tachycar-
dia or other high-risk disease profiles. Stroke or a transient
ischemic attack related to atrial fibrillation occurred in six
patients of five families between 51 and 64 years of age.
Two of these patients had persisting disabling symptoms.
Two patients with stroke and two with a transient
ischemic attack recovered without permanent impair-
ment.
Genotype-phenotype correlation
Sudden death as the most serious adverse event was prev-
alent in seven of 18 families (39%). However, despite
missense mutations were most frequent with seven of 18
index cases, none of the sudden deaths was observed in
families of these patients. In contrast, sudden deaths
occurred in three of four families with splice mutations, in
two of three with nonsense mutations, in one of three
with frameshift mutations and in the single family with an
in-frame codon deletion. All three families with sudden
deaths at or before the age of 35 years were carriers of
splice mutations.
Discussion
Mutations in the MYBPC3 gene are among the most prev-
alent causes of inherited HCM. In earlier studies, e.g.
[6,7], MYBPC3  mutations were found to be associated
with a low penetrance, late onset and a benign course of
the disease. This notion became challenged, however, by
the findings of two recent studies. In the first, carriers of a
specific MYBPC3 frameshift mutation from 15 unrelated
Conservation of mutated MYBPC3 amino acid residues  throughout different species Figure 2
Conservation of mutated MYBPC3 amino acid resi-
dues throughout different species.
I336V        T957S
Human      SEYERIAFQYG  PGAPVTTTEPV 
Dog        SEYERIAFQHG  PGAPVTTQEPV 
Cattle     SEYERIAFQHG  AGPPVTTKEPV 
Claw frog  SEYEKIAFQYG  PSEPCTMKEPV 
Zebrafish  SEYEKIAFQYG  PSAPATLQQAV BMC Medical Genetics 2008, 9:95 http://www.biomedcentral.com/1471-2350/9/95
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Table 3: Adverse events in families of MYBPC3 mutation carriers
Fam or single patient Patient Confirmed mutation carrier Age at event Type of event
1 II-9 Yes 54 Transient ischemic attack
2 II-1 Yes 55 Stroke
II-4 No* 49 ICD†
6 I-2 No* 35 Sudden death
7 Yes 51 Stroke
8 II-1 Yes 49 Pacemaker (Sick sinus syndrome)
9 Yes 59 Palpitations, positive EPS‡, ICD†
11 I-2 No* 55 Sudden death
II-2 No* 36 Sudden death
12 I-1 No* 42 Sudden death
II-3 No* 33 Sudden death
II-6 Yes 67 Inferior MI, coronary heart disease
67 ICD†: Non-sustained VT (holter)
III-3 Yes 42 ICD†: Non-sustained VT (holter)
IV-3 No* 13 Sudden death
13 I-1 No* 64 Stroke
67 Sudden death
II-1 No* 53 Transient ischemic attack
14 I-1 No* 53 Sudden death
16 II-1 No* 32 Sudden death
II-3 Yes 58 Heart transplantation
II-5 Yes 61 Resuscitation due to ventricular fibrillation, ICD†
67 Heart failure related death
III-9 Yes 45 Sudden death
17 II-3 Yes 64 Stroke
18 I-2 No* 42 Sudden death
*First degree relative with mutation; †ICD: implantable cardioverter defibrillator; ‡EPS: electro-physiological study (programmed ventricular 
stimulation)BMC Medical Genetics 2008, 9:95 http://www.biomedcentral.com/1471-2350/9/95
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families revealed a high penetrance, early onset and
malignant course of the disease [20]. In the second, a high
proportion of MYBPC3 mutations was found in children
with HCM [21]. Here we screened 87 patients with HCM
and 71 patients with DCM for mutations in MYBPC3 and
correlated the genotypes, phenotypes and clinical out-
comes of the mutation carriers and their close relatives.
We identified 18 different mutations in 18 index patients,
16 with HCM and 2 with DCM. Mutations in other likely
candidate genes for HCM and DCM were excluded. In
addition to the 18 index patients, 24 more MYBPC3 muta-
tion carriers were detected among relatives, distributed
over ten families. In ten of them, the presence of a cardio-
myopathy was unknown before. 16 of the 24 additional
mutation carriers displayed a clear disease phenotype.
Additional three individuals had a borderline phenotype:
One of them had hypertension as potential cause of sec-
ondary hypertrophy and coronary artery disease. Two
more and still young individuals, a 17 year old male (IV-
2 of family 17) and a 15 year old female (III-5 of family
18), showed also borderline signs of the disease. Only
three mutation carriers, all members of family 5, had no
certain pathological findings. The corresponding muta-
tion, a novel p.R272C missense mutation, altered one of
three known phoshorylation motifs of the MYBP-C pro-
tein [16]. We found decreased phosphorylation at this
position in vitro, but we don't know the functional conse-
quences  in vivo. In this family, only the index patient
showed a DCM phenotype, for which a different cause,
e.g. hypertensive heart disease, cannot be ruled out. The
other family with a DCM phenotype of the index patient
was family 16 with a novel splice site mutation. Two older
mutation carriers suffered from DCM, while four younger
patients from the following generation either showed
symptoms of HCM or at least a HCM phenotype upon car-
diac MRI examination. It is most likely that the two older
patients suffered from an end-stage HCM with progres-
sion to a DCM phenotype, as had been described already
in a few cases of MYH7 and MYBPC3 mutation carriers
[22]. For still unknown reasons, the number of MYBPC3
mutations associated with DCM is much lower [23] than
the number of MYBPC3 mutations associated with HCM.
Contrasting to previous findings in families with MYBPC3
mutations [7], malignant clinical events were frequently
observed in our families, even at a young age. Sudden car-
diac deaths at or even before the age of 35 did occur in
four members of families 6, 12 and 16. In accordance with
current recommendations [4], these data underscore the
importance of a close meshed risk stratification in every
patient at risk due to a mutation in MYBPC3. Although the
number of mutations is too small to prove statistically sig-
nificant, it is remarkable that all sudden deaths at or
before the age of 35 occurred in families with splice muta-
tions, while no sudden death was observed in families
with missense mutations. Stroke and peripheral emboli-
zations had been reported by others in 6% of HCM
patients, with an incidence of 0.8% per year [24]. As sev-
eral factors in HCM are favouring manifestation of atrial
fibrillation, it is not surprising that in five of 18 families a
history of stroke or transient ischemic attack was preva-
lent. Therefore, clinical care of patients and family mem-
bers at risk should consider risk indicators for atrial
fibrillation like left atrial enlargement, severe diastolic
dysfunction or family history of stroke or high susceptibil-
ity for atrial fibrillation.
A major limitation of our study is that genotype and phe-
notype data of deceased family members are not available
in most cases. At a more advanced age, alternative causes
of sudden death like myocardial infarction and atrial
fibrillation become more likely. Therefore, only a well
documented sudden death below 35 years of age is an
accepted criterion for familial involvement in a cardiomy-
opathy [12]. In our retrospective evaluation of affected
families, it cannot be excluded, that other conditions may
have led to the adverse events. Nevertheless, it is notewor-
thy that in many of our families adverse events are preva-
lent in first-degree relatives at both older and younger
ages, while MYBPC3 mutations initially were believed to
be associated with a good prognosis. However, a referral
bias in our observational study cannot be excluded,
although the reason for presentation in virtually all index
patients were diagnostic procedures to rule out concomi-
tant coronary artery disease, but not adverse events. Muta-
tions in other likely candidate genes for HCM were not
found in any of the index patients. As to the heterogeneity
of the genetic causes of cardiomyopathies, additional
mutations in less likely or hitherto unknown disease
genes cannot be excluded. Moreover, yet unknown dis-
ease modifiers might have had a modulating effect on the
disease phenotype. The question of the prognostic impact
of certain mutations in cardiomyopathies has to be clari-
fied by inclusion of mutations carriers into registries.
Conclusion
The finding of a MYBPC3 gene mutation is not generally
associated with a good prognosis. Therefore, MYBPC3
mutation carriers should be as well subjected to careful
clinical risk stratification.
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